Breaking News, Collaborations & Alliances

AATec Medical & Northway Biotech Develop ATL-105

The two companies will develop and scale production for a novel recombinant version of alpha-1 antitrypsin targeting lung diseases.

By: Rachel Klemovitch

Assistant Editor

AATec Medical GmbH (AATec), a biotech company developing a multi-product platform to treat respiratory diseases, and Northway Biotech (NBT), a global CDMO, partnered for manufacturing process development and analytical development of AATec’s lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB). Per the agreement, NBT will leverage its expertise in biologics manufacturing to develop and scal...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters